retatrutide type 2 diabetes phase 2 trial Effects of on body composition in people with diabetes: a substudy of a 2, double-blind, parallel-group, placebo-controlled, randomised The data just dropped —

A Phase 2a randomised trial published in Nature Medicine (2024) found that Retatrutide produced an 81.4% (8mg) and 82.4% (12mg) relative reduction in liver fat at 24 weeks, the most significant hepatic fat reduction recorded for a peptide of this class

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept

User community feedback supplements formal testing

Similarly, those with higher starting body weight may see more substantial weight loss, but the rate of loss varies considerably between individuals

It slows digestion, helping you feel full longer, while reducing cravings and regulating blood sugar

Outcome: Patients were observed from first prescription of medication to diagnosis of defined GI adverse events, based on ICD-9/ICD-10 codes or end of the study period in 2020